AKT1S1 Recombinant Monoclonal Antibody

1. The Akt-PRAS40 pathway is activated by uric acid, which inhibits autophagy and recapitulates the uric acid-induced proinflammatory cytokine phenotype. PMID: 28484006
2. crystal structures of RAPTOR-TOS motif complexes that define the determinants of TOS recognition, of an mTOR FKBP12-rapamycin-binding (FRB) domain-substrate complex that establishes a second substrate-recruitment mechanism, and of a truncated mTOR-PRAS40 complex that reveals PRAS40 inhibits both substrate-recruitment sites PMID: 29236692
3. Study found that activated PRAS40 acts not only as a regulator of TGFA-triggered exosome secretion but also as a common regulator of distinct microenvironmental and oncogenic signal-triggered exosome secretion in both normal and tumor cell types. PRAS40 is the first regulator identified for stress-induced exosome secretion. PMID: 28674187
4. PRAS40 was downregulated in the DU145 cells following MYO6 knockdown. PMID: 27431378
5. Phosphorylation of S202/203 of AKT1S1 by PKM2 released AKT1S1 from raptor and facilitated its binding to 14-3-3, resulted in hormonal- and nutrient-signals independent activation of mTORC1 signaling and led accelerated oncogenic growth and autophagy inhibition in cancer cells. PMID: 26876154
6. The frameshift mutation detected in the current study would result in a premature stop of amino-acid synthesis in AKT1S1 protein and hence resembles a typical loss-of-function mutation. PMID: 25648575
7. Supporting this idea, we identified a downstream target of the TGFb-miR-96 signaling pathway to be AKT1S1 mRNA, whose translated protein is a negative regulator of mTOR kinase. PMID: 25531317
8. This review discusses the role of PRAS40 and possible feedback mechanisms, and alterations in AKT/PRAS40/mTOR signaling that have been implicated in the pathogenesis of tumor progression. [review] PMID: 26003731
9. Findings indicate that dual phosphorylation of PRAS40 by Akt and mTORC1 promotes formation of a nuclear-specific PRAS40- and RPL11-containing complex distinct from mTORC1 that inhibits the RPL11-HDM2-p53 pathway. PMID: 24704832
10. PRAS40 as a regulator of insulin sensitivity in hSkMC PMID: 24576065
11. PRAS40 contains a functional nuclear export signal. Furthermore, enforced nuclear accumulation of PRAS40 impairs insulin action, thereby substantiating the function of this protein in the regulation of insulin sensitivity. PMID: 23712034
12. Data suggest that PRAS40 modulates insulin action in skeletal muscle; knockdown of PRAS40 inhibits insulin action in cultured myotubes and is associated with up-regulation of IRS1 (insulin receptor substrate 1) degradation via proteasome proteolysis. PMID: 23460019
13. WISP1 governs PRAS40 by sequestering PRAS40 intracellularly through post-translational phosphorylation. PMID: 22873724
14. study found tuberin and PRAS40 to be potent anti-apoptotic gatekeepers in early stem-cell differentiation; data allow new insights into the regulation of early stem-cell maintenance and differentiation and identify a new role of the tumor suppressor tuberin and the oncogenic protein PRAS40 PMID: 22090422
15. This review summarizes the regulation and potential function(s) of PRAS40 in the complex Akt- and mTOR-signaling network in health and disease--{REVIEW} PMID: 22354785
16. our findings suggest that PRAS40 promotes the development of ESFT PMID: 22241085
17. PRAS40 is known for its ability to regulate the mammalian target of rapamycin complex 1 kinase activity, possessing a key regulatory role at the cross point of signal transduction pathways activated by growth factor receptors PMID: 21906675
18. phosphorylation of PRAS40 is critical for the activation of mTOR in CNI-induced VEGF overexpression and renal cancer progression. PMID: 21886838
19. dissociation of PRAS40 from insulin-stimulated 4E-BP protein binding to mTORC1 and enhanced mTORC1 substrate binding results from Akt and mTORC1 activation and makes little or no contribution to mTORC1 signaling PMID: 21914810
20. PIM1-activated pPRAS40, AKT-activated pFOXO3a, and their complex formation with 14-3-3 could be key regulators of the radiation-induced radioresistance in NSCLC cells PMID: 21910584
21. PRAS40 is an important regulator of insulin sensitivity of the Akt-mTOR pathway and a potential target for the treatment of cancers, insulin resistance and hamartoma syndromes. PMID: 17277771
22. PRAS40 inhibits cell growth, S6K1 phosphorylation, and rheb-induced activation of the mTORC1 pathway PMID: 17386266
23. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. PMID: 17510057
24. PRAS40 acts downstream of mTORC1 but upstream of its effectors, such as S6K1 and 4E-BP1 PMID: 17604271
25. activation of mTORC1 signalling by phorbol esters does not require PRAS40 to be phosphorylated at Thr(246), bind to 14-3-3 or be released from mTORC1. PMID: 18215133
26. after mTORC1 kinase activation by upstream regulators, PRAS40 is phosphorylated directly by mTOR, thus contributing to the relief of PRAS40-mediated substrate competition. PMID: 18372248

Show More

Hide All

HGNC: 28426

OMIM: 610221

KEGG: hsa:84335

STRING: 9606.ENSP00000341698

UniGene: Hs.515542